TapewireFind a company

person · Reporting owner

HILZINGER KURT J

Disclosed activity across 2 companies

Tapewire entity
33645
SEC CIK
0001191504

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HUMANA INCHUM · Entity 1429DirectorSeptember 30, 2026October 02, 2026
Outlook Therapeutics, Inc.OTLK · Entity 608DirectorMay 26, 2026May 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HUMANA INC

Report date September 30, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect16,772 Reported balance After 2026-09-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-09-30 · Grant · Acquired 238 · Balance 16,772

F3: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect24,800 Reported balance Holding disclosure · report date 2026-09-30 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance 24,800

F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect3,364 Reported balance Holding disclosure · report date 2026-09-30 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance 3,364

F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

Humana CommonSEC Table I · non-derivativeDirect19,448 Reported balance Holding disclosure · report date 2026-09-30 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 19,448

Filing footnotes · ownership attribution and instrument terms

F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.

F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F3: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.

Outlook Therapeutics, Inc.

Report date May 26, 2026 · Filed May 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect423,655 Reported balance After 2026-05-26 transaction · row 1
1 source row

Row 1 · 2026-05-26 · Purchase · Acquired 400,000 · Balance 423,655

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 31, 2021 Filed Jan 4, 2022 14:38 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 212 $465.85 $98,760.20
Disclosure

SEC source: 0001062993-22-000113 · form4.xml · derivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,679

Underlying: Humana Common · 212 shares

Expires not disclosed

F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

Read SEC document
October 05, 2021 Filed Oct 7, 2021 21:03 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 34,425 $0.00 Strike: $2.12 $0.00
Disclosure

SEC source: 0001209191-21-059948 · doc4.xml · derivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,425

Underlying: Common Stock · 34,425 shares

Expires 2031-10-05

F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 13:38 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 209 $394.00 $82,344.96
Disclosure

SEC source: 0000049071-21-000127 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,071

Underlying: Humana Common · 209 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
June 30, 2021 Filed Jul 2, 2021 15:18 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 194 $442.72 $85,886.71
Disclosure

SEC source: 0000049071-21-000103 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,862

Underlying: Humana Common · 194 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
March 31, 2021 Filed Apr 2, 2021 13:53 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 199 $422.60 $84,097.40
Disclosure

SEC source: 0000049071-21-000071 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,668

Underlying: Humana Common · 199 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
March 24, 2021 Filed Mar 26, 2021 22:05 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 20,873 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0001209191-21-023278 · doc4.xml · derivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,873

Underlying: Common Stock · 20,873 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
January 04, 2021 Filed Jan 5, 2021 18:01 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 403 $0.00 $0.00
Disclosure

SEC source: 0000049071-21-000005 · edgar.xml · derivative · entry 5

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403

Underlying: Humana Common · 403 shares

Expires not disclosed

F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021.

Read SEC document
December 31, 2020 Filed Jan 5, 2021 18:01 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 218 $407.16 $88,759.79
Disclosure

SEC source: 0000049071-21-000005 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,469

Underlying: Humana Common · 218 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
December 31, 2020 Filed Jan 5, 2021 18:01 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 227 $407.16 $92,424.19
Disclosure

SEC source: 0000049071-21-000005 · edgar.xml · derivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,467

Underlying: Humana Common · 227 shares

Expires not disclosed

F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

Read SEC document
October 05, 2020 Filed Oct 5, 2020 22:42 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 116,708 $0.51 Strike: $0.71 $59,999.58
Disclosure

SEC source: 0001209191-20-053866 · doc4.xml · derivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,708

Underlying: Common Stock · 116,708 shares

Expires 2030-10-05

F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 22:42 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 217,602 $0.00 Strike: $0.71 $0.00
Disclosure

SEC source: 0001209191-20-053866 · doc4.xml · derivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,602

Underlying: Common Stock · 217,602 shares

Expires 2030-10-01

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
September 30, 2020 Filed Oct 2, 2020 21:43 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 207 $410.09 $84,889.15
Disclosure

SEC source: 0000049071-20-000125 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,251

Underlying: Humana Common · 207 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
July 17, 2020 Filed Jul 21, 2020 22:07 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 210,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-20-043221 · doc4.xml · derivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2030-07-17

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
June 30, 2020 Filed Jul 2, 2020 21:29 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 235 $384.15 $90,275.25
Disclosure

SEC source: 0000049071-20-000098 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,044

Underlying: Humana Common · 235 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
March 31, 2020 Filed Apr 2, 2020 15:40 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 239 $308.22 $73,663.39
Disclosure

SEC source: 0000049071-20-000075 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,809

Underlying: Humana Common · 239 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
March 19, 2020 Filed Mar 20, 2020 21:53 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $0.54 $0.00
Disclosure

SEC source: 0001209191-20-020510 · doc4.xml · derivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-03-19

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:58 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 453 $0.00 $0.00
Disclosure

SEC source: 0000049071-20-000010 · edgar.xml · derivative · entry 5

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 453

Underlying: Humana Common · 453 shares

Expires not disclosed

F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:58 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 239 $366.09 $87,494.32
Disclosure

SEC source: 0000049071-20-000010 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,570

Underlying: Humana Common · 239 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:58 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 196 $366.09 $71,752.66
Disclosure

SEC source: 0000049071-20-000010 · edgar.xml · derivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,240

Underlying: Humana Common · 196 shares

Expires not disclosed

F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

Read SEC document
October 03, 2019 Filed Oct 7, 2019 22:07 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 60,893 $0.99 Strike: $1.40 $59,997.87
Disclosure

SEC source: 0001209191-19-052708 · doc4.xml · derivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,893

Underlying: Common Stock · 60,893 shares

Expires 2029-10-03

F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 03, 2019 Filed Oct 7, 2019 22:07 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.40 $0.00
Disclosure

SEC source: 0001209191-19-052708 · doc4.xml · derivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-10-03

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
September 30, 2019 Filed Oct 2, 2019 14:26 UTC HUMANA INC HUM · Entity 1429 GrantStock Unit · Derivative 331 $255.05 $84,419.90
Disclosure

SEC source: 0000049071-19-000096 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,331

Underlying: Humana Common · 331 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
June 28, 2019 Filed Jul 2, 2019 16:08 UTC HUMANA INC HUM · Entity 1429 GrantStock Unit · Derivative 328 $263.21 $86,332.88
Disclosure

SEC source: 0000049071-19-000074 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Humana Common · 328 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
March 29, 2019 Filed Apr 2, 2019 15:12 UTC HUMANA INC HUM · Entity 1429 GrantStock Unit · Derivative 329 $263.97 $86,844.49
Disclosure

SEC source: 0000049071-19-000055 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,672

Underlying: Humana Common · 329 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
February 04, 2019 Filed Feb 6, 2019 22:57 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 5,983 $0.80 $4,786.40
Disclosure

SEC source: 0001209191-19-007844 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,947

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7679 - $0.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 01, 2019 Filed Feb 1, 2019 23:25 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 8,200 $0.77 $6,314.00
Disclosure

SEC source: 0001209191-19-006603 · doc4.xml · nonDerivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,964

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.745 - $0.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 31, 2019 Filed Feb 1, 2019 23:25 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 6,300 $0.75 $4,725.00
Disclosure

SEC source: 0001209191-19-006603 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,764

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.729 - $0.7695, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 30, 2019 Filed Feb 1, 2019 23:25 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 4,890 $0.72 $3,520.80
Disclosure

SEC source: 0001209191-19-006603 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,464

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.71 - $0.7375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 29, 2019 Filed Jan 30, 2019 00:01 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 5,400 $0.73 $3,942.00
Disclosure

SEC source: 0001209191-19-005917 · doc4.xml · nonDerivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,574

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 - $0.7357, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 28, 2019 Filed Jan 30, 2019 00:01 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 15,884 $0.71 $11,277.64
Disclosure

SEC source: 0001209191-19-005917 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,174

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.679 - $0.7467, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 25, 2019 Filed Jan 30, 2019 00:01 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 10,828 $0.69 $7,471.32
Disclosure

SEC source: 0001209191-19-005917 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,290

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 - $0.699, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 23, 2019 Filed Jan 25, 2019 00:51 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 2,266 $0.67 $1,518.22
Disclosure

SEC source: 0001209191-19-005247 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,462

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 - $0.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 22, 2019 Filed Jan 25, 2019 00:51 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 10,749 $0.68 $7,309.32
Disclosure

SEC source: 0001209191-19-005247 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,196

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6605 - $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 17, 2019 Filed Jan 18, 2019 21:51 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 2,300 $0.69 $1,587.00
Disclosure

SEC source: 0001209191-19-004571 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,447

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 - $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 16, 2019 Filed Jan 18, 2019 21:51 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 800 $0.68 $544.00
Disclosure

SEC source: 0001209191-19-004571 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,147

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.68 - $0.687, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2019 Filed Jan 16, 2019 22:31 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 2,266 $0.70 $1,586.20
Disclosure

SEC source: 0001209191-19-003962 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,347

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.666 - $0.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 14, 2019 Filed Jan 16, 2019 22:31 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 4,399 $0.71 $3,123.29
Disclosure

SEC source: 0001209191-19-003962 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,081

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.68 - $0.7143, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 10, 2019 Filed Jan 11, 2019 22:18 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 6,053 $0.70 $4,237.10
Disclosure

SEC source: 0001209191-19-003446 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,682

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.685 - $0.7493, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 09, 2019 Filed Jan 11, 2019 22:18 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 2,792 $0.73 $2,038.16
Disclosure

SEC source: 0001209191-19-003446 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,629

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.70 - $0.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 08, 2019 Filed Jan 9, 2019 01:13 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 6,410 $0.65 $4,166.50
Disclosure

SEC source: 0001209191-19-002918 · doc4.xml · nonDerivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,837

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 - $0.695, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 07, 2019 Filed Jan 9, 2019 01:13 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 5,166 $0.63 $3,254.58
Disclosure

SEC source: 0001209191-19-002918 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,427

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 - $0.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 04, 2019 Filed Jan 9, 2019 01:13 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 6,205 $0.59 $3,660.95
Disclosure

SEC source: 0001209191-19-002918 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,261

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.57 - $0.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 03, 2019 Filed Jan 3, 2019 23:01 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 4,200 $0.59 $2,478.00
Disclosure

SEC source: 0001209191-19-001265 · doc4.xml · nonDerivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,056

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5472 - $0.623, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 02, 2019 Filed Jan 3, 2019 21:31 UTC HUMANA INC HUM · Entity 1429 GrantRestricted Stock Units · Derivative 588 $0.00 $0.00
Disclosure

SEC source: 0000049071-19-000004 · edgar.xml · derivative · entry 5

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 588

Underlying: Humana Common · 588 shares

Expires not disclosed

F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019.

Read SEC document
January 02, 2019 Filed Jan 3, 2019 23:01 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 1,640 $0.59 $967.60
Disclosure

SEC source: 0001209191-19-001265 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,856

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.51 - $0.601, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
December 31, 2018 Filed Jan 3, 2019 21:31 UTC HUMANA INC HUM · Entity 1429 GrantStock Unit · Derivative 284 $284.57 $80,816.46
Disclosure

SEC source: 0000049071-19-000004 · edgar.xml · derivative · entry 4

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,343

Underlying: Humana Common · 284 shares

Expires not disclosed

F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).

Read SEC document
December 31, 2018 Filed Jan 3, 2019 21:31 UTC HUMANA INC HUM · Entity 1429 GrantStock Unit · Derivative 182 $284.57 $51,790.83
Disclosure

SEC source: 0000049071-19-000004 · edgar.xml · derivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,044

Underlying: Humana Common · 182 shares

Expires not disclosed

F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

Read SEC document
December 31, 2018 Filed Jan 3, 2019 23:01 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 11,349 $0.59 $6,695.91
Disclosure

SEC source: 0001209191-19-001265 · doc4.xml · nonDerivative · entry 1

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,216

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 - $0.6031, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
December 28, 2018 Filed Dec 28, 2018 22:06 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 11,910 $0.52 $6,193.20
Disclosure

SEC source: 0001209191-18-064336 · doc4.xml · nonDerivative · entry 3

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,867

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.45 - $0.5845, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
December 27, 2018 Filed Dec 28, 2018 22:06 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 730 $0.51 $372.30
Disclosure

SEC source: 0001209191-18-064336 · doc4.xml · nonDerivative · entry 2

HILZINGER KURT J · CIK 0001191504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,957

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.45 - $0.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.